What's Happening?
Innovent Biologics has announced promising results from a Phase 1 proof-of-concept clinical study of its PD-1/IL-2α-bias bispecific fusion protein, IBI363, in treating advanced immunotherapy-resistant non-small cell lung cancer (NSCLC). The study, presented
at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, involved 136 subjects with NSCLC who received IBI363 monotherapy. The results showed significant survival benefits, particularly in patients with squamous NSCLC and those with a smoking history. The median overall survival (OS) for patients in the 3 mg/kg dose group reached 18.2 months for squamous NSCLC and 15.2 months for adenoNSCLC. The study also highlighted a favorable safety profile for IBI363, with manageable adverse events.
Why It's Important?
The findings from Innovent's study are significant as they offer a potential new treatment option for patients with NSCLC who have limited options after failing immunotherapy. The robust survival benefits observed in the study could address the unmet medical need for effective treatments in this patient population. The dual mechanism of IBI363, combining immune checkpoint blockade with cytokine agonism, may provide durable long-term survival benefits, offering hope for improved outcomes in a challenging therapeutic area. This development could influence future treatment protocols and encourage further research into bispecific fusion proteins.
What's Next?
Following the promising results, IBI363 has entered a global Phase 3 clinical study for immunotherapy-resistant squamous NSCLC. Innovent, in collaboration with Takeda, plans to initiate a global Phase 3 study for non-squamous NSCLC, pending regulatory communications. The ongoing research and development efforts aim to expand the use of IBI363 across various tumor types and settings, potentially leading to broader approval and commercialization. The collaboration with Takeda also suggests a strategic approach to bringing this therapy to a wider market, particularly in the U.S. and globally.
